BioCryst Pharmaceuticals (BCRX) News Today

BNP Paribas Financial Markets reduced its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 78.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 167,782 shares of the biotechnology co

Vanguard Group Inc. lifted its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 15.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 17,763,720 shares of the biotechnology company's stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has been given a consensus recommendation of "Buy" by the seven analysts that are currently covering the company, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year p

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 6.5%

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) was the recipient of a large decrease in short interest in June. As of June 15th, there was short interest totalling 29,670,000 shares, a decrease of 18.0% from the May 31st total of 36,180,000 shares. Based on an average daily volume of 3,660,000 shares, the days-to-cover ratio is currently 8.1 days.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) Director Amy E. Mckee sold 8,600 shares of the business's stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $6.32, for a total value of $54,352.00. Following the completion of the sale, the director now directly owns 27,831 shares of the company's stock, valued at $175,891.92. The sale was disclosed in a legal filing with the SEC, which is available through this link.

BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 4.2%

Fisher Asset Management LLC lessened its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 9.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,884,569 shares of the biotechnology company's stock after selling 300,63

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) Director Machelle Sanders sold 4,689 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $6.00, for a total value of $28,134.00. Following the completion of the transaction, the director now owns 27,742 shares in the company, valued at $166,452. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Braidwell LP grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 6.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,718,477 shares of the biotechnology company's stock

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have earned an average recommendation of "Buy" from the seven ratings firms that are currently covering the stock, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 1-year price objective

Avoro Capital Advisors LLC lifted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 13.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,050,000 shares

Rafferty Asset Management LLC raised its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 18.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 95

Norges Bank purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 2,216,612 shares of the biotechnology company's stock, valued at approximately $13,278

BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 7.3% Following Insider Buying Activity

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) Director Alan G. Levin bought 7,861 shares of the stock in a transaction on Thursday, May 30th. The stock was acquired at an average price of $6.36 per share, with a total value of $49,995.96. Following the completion of the acquisition, the director now owns 44,951 shares of the company's stock, valued at approximately $285,888.36. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Charles Schwab Investment Management Inc. boosted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 9.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,594,436 shares of the biotec

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) Director Steve Aselage bought 2,500 shares of the stock in a transaction on Friday, May 24th. The shares were acquired at an average price of $6.40 per share, with a total value of $16,000.00. Following the purchase, the director now owns 2,500 shares of the company's stock, valued at $16,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Aigen Investment Management LP decreased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 91.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 12,670 shares of the biotechnology company's stock after selling 1

Trexquant Investment LP decreased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 28.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 421,516 shares of the biotechnology company's st

GW&K Investment Management LLC reduced its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 9.1% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,337,683 shares of the biotechnology company's

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) Director Nancy J. Hutson acquired 5,000 shares of the company's stock in a transaction on Monday, May 20th. The shares were bought at an average cost of $6.38 per share, with a total value of $31,900.00. Following the acquisition, the director now directly owns 86,818 shares in the company, valued at $553,898.84. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 4.4%

BNP Paribas Financial Markets increased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 45.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 790,163 shares of the biotechnology company's stock after purchasing an additional 247,195

Assenagon Asset Management S.A. cut its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 26.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 386,885 shares of the biotechnolo

Jump Financial LLC cut its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 68.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 128,771 shares of the biotechnology c

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up on Insider Buying Activity

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) Director Steven K. Galson purchased 21,940 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, May 13th. The shares were acquired at an average cost of $5.49 per share, with a total value of $120,450.60. Following the transaction, the director now directly owns 51,551 shares in the company, valued at $283,014.99. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.